Jeffrey Tate - Cyclo Therapeutics CEO
CEO
Dr. Jeffrey L. Tate, Ph.D., is Chief Operating Officer, Chief Scientific Officer, Director of CTD Holdings Inc. Dr. Tate was President and CEO of NanoSonic Products, Inc., and Sphingo Biotechnology, Inc., whollyowned subsidiaries of the Company since 2010. From January 2007 to February 2010, he was president of JJireh Products, Incorporated, a company that develops and markets products manufactured using pulse drying technology. From January 1995 to December 2006, Dr. Tate served as a principal of J. Benson Tate Consultants LLC, a management consulting company. From July 1999 to January 2005, Dr. Tate served as Vice President of Scientific and Regulatory Affairs of Natural Biologics, LLC, a pharmaceutical company since 2015.
| Age | 56 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Phone | 386 418 8060 |
| Web | http://www.ctd-holdings.com |
Cyclo Therapeutics Management Efficiency
The company has return on total asset (ROA) of (111.53) % which means that it has lost $111.53 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (601.41) %, meaning that it created substantial loss on money invested by shareholders. Cyclo Therapeutics' management efficiency ratios could be used to measure how well Cyclo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 198.78 K in liabilities with Debt to Equity (D/E) ratio of 1.2, which is about average as compared to similar companies. Cyclo Therapeutics has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cyclo Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Cyclo Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cyclo Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cyclo to invest in growth at high rates of return. When we think about Cyclo Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 10 records | CEO Age | ||
| Dean Connor | Sun Life Financial | 63 | |
| Alan Colberg | Assurant | 58 | |
| Michael Kehoe | Kinsale Capital Group | 58 | |
| Barry McCarthy | Deluxe | 60 | |
| Lee Schram | Deluxe | 55 | |
| Gene Mergelmeyer | Assurant | 61 | |
| William McCarthy | Deluxe | 64 | |
| Adam Lamnin | Assurant | 50 | |
| Nhon Luc | Sun Life Financial | N/A | |
| Craig Lemasters | Assurant | 53 | |
Management Performance
| Return On Equity | -601.41 | |||
| Return On Asset | -111.53 |
Cyclo Therapeutics Leadership Team
Elected by the shareholders, the Cyclo Therapeutics' board of directors comprises two types of representatives: Cyclo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyclo. The board's role is to monitor Cyclo Therapeutics' management team and ensure that shareholders' interests are well served. Cyclo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyclo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nathan Fine, Executive Chairman of the Board, CEO | ||
| George Fails, Executive VP, Operations Manager, Director and Member of Nomination and Governance Committee | ||
| Jeffrey Tate, CEO and President Director, Member of Audit Committee, CEO of Nanosonic Products Inc, CEO of Sphingo Biotechnology, Inc. and President of Nanosonic Products Inc and President of Sphingo Biotechnology, Inc | ||
| William Shanahan, Director | ||
| Scott Fine, Chairman, CEO, Chairman of Audit Committee and Chairman of Nomination and Governance Committee | ||
| C Strattan, Director, Member of Compensation Committee and CEO of CTD, Inc. | ||
| Markus Sieger, Director | ||
| Joseph Farnan, Director | ||
| Joshua Fine, CFO | ||
| Sharon Hrynkow, Sr. VP for Medical Affairs and Member of Scientific Advisory Board | ||
| Patrick Ostronic, Independent Director | ||
| Randall Toig, Director |
Cyclo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cyclo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -601.41 | |||
| Return On Asset | -111.53 | |||
| Operating Margin | (905.22) % | |||
| Current Valuation | 10.71 M | |||
| Shares Outstanding | 169.98 M | |||
| Shares Owned By Insiders | 1.20 % | |||
| Shares Owned By Institutions | 0.21 % | |||
| Price To Earning | (6.45) X | |||
| Price To Book | 4.75 X | |||
| Price To Sales | 10.87 X |
Pair Trading with Cyclo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclo Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Cyclo Therapeutics information on this page should be used as a complementary analysis to other Cyclo Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Cyclo OTC Stock
If you are still planning to invest in Cyclo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyclo Therapeutics' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |